TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04647617

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Quantitative weight -bearing and report exercise sign data every weekly
Description: keep their normal live style

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative weight -bearing and report exercise sign data every weekly
Description: keep their normal live style
Study: NCT02328820

Intervention type: OTHER
Group type: OTHER
Intervention: Percutaneous coronary intervention (PCI)
Description: For lesions with both FFR\<=0.8 and CFR\<2.0

Intervention type: OTHER
Group type: OTHER
Intervention: Optimal medical therapy (OMT)
Description: For lesions with FFR\>0.8 or CFR\>=2.0 or both
Study: NCT05680792

Intervention type: DRUG
Group type: OTHER
Intervention: Nitazoxanide
Description: 1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Nitazoxanide
Description: 1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir/ritonavir
Description: 300/100 mg atazanavir/ritonavir tablets in the evening once daily, to be administered after meal for 5 days.
Study: NCT01825837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 1800 mg once daily [Group 1 (Part II)]
Description: BIA 2-093 1800 mg taken orally in the evening, for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 900 mg once daily [Group 2 (Part II)]
Description: BIA 2-093 900 mg taken orally in the evening, for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 300 mg once daily [Group 3 (Part II)]
Description: BIA 2-093 300 mg taken orally in the evening, for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 900 mg (Part I)
Description: In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
Study: NCT03795584

Intervention type: PROCEDURE
Intervention: sterile repositionable hemostasis clipping device close the large duodenal papilla incision
Description: After the bile duct stent was placed, the investigators can use sterile repositionable hemostasis clipping device to close large duodenal papilla incision at 11 o'clock on the duodenal papilla.
Study: NCT02427984

Intervention type: OTHER
Intervention: Metal ions dosage and evaluation of local/systemic reaction
Description: Dosage of Chromium and Cobalt on several biological matrices deriving from each patients.~Determination of local/systemic reaction

Intervention type: OTHER
Intervention: Noise registration and metal ions determination
Description: Dosage of Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of range of noise

Intervention type: OTHER
Intervention: Metal ions dosage, evaluation of local/systemic reaction, noise registration
Description: Dosage of Chromium, Cobalt, Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of local/systemic reaction
Study: NCT04030013

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group education
Description: All patients of group 1 and 2 will receive intensive education for 3-4 months, then refreshment session every 3 months for 2 years. Initially, patient data will be collected through 3 types of forms: patient identification form, metabolic control parameters form and diabetes self-care scale questionnaire; then every 6 months metabolic parameters and diabetes self-care scale questionnaire will be reassessed.
Study: NCT04263337

Intervention type: DRUG
Group type: OTHER
Intervention: [11C] PiB
Description: Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: [11C] PiB
Description: Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: [11C] PiB
Description: Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: [11C] PiB
Description: Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Study: NCT01090492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
Study: NCT04178343

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: 1. the prescription of tomotherapy: whole brain radiation (WBRT) with 40Gy in 20 fractions and concurrent boost of 60Gy of the leptomeningeal metastases;~2. WBRT of 50Gy in 25 fractions, with dose limitation of hippocampus and brain stem; c.TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.~d. Some patients received intrathecal chemotherapy (MTX+AraC+Dex) based on the cytology of cerebrospinal fluid (CSF).
Study: NCT01090492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00489791
Description: Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
Study: NCT03476109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomisation to omalizumab
Description: The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
Study: NCT00945893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]
Description: 0.5 mL; (intranasal sprayer)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
Study: NCT01768286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT01796509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical, psychological, social
Description: After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
Study: NCT03476109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomisation to mepolizumab
Description: The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
Study: NCT01602120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lampalizumab
Description: Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
Study: NCT01981330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aMSC
Description: aMSC injected into the vocal fold of the patient
Study: NCT01147523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone/Vitamin E
Description: Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
Study: NCT05247775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Profilometry
Description: Profilometry was performed in 43 patients before open retropubic radical prostatectomy.
Study: NCT04861909

Intervention type: DEVICE
Intervention: AT LISA tri 839MP
Description: Non interventional study
Study: NCT01981330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aMSC+hyaluronan gel
Description: aMSC+ hyaluronan gel is injected into the patients vocal fold
Study: NCT03663101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
Study: NCT03663101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
Study: NCT01358045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Application on the lesion 2 times a day 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac + Calcitriol
Description: Application on the lesion 2 times a day, both ointments, 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Application on the lesion, 2 times a day, 8 weeks.
Study: NCT04263337

Intervention type: DRUG
Group type: OTHER
Intervention: [18F] PBR111
Description: Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F] PBR111
Description: Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F] PBR111
Description: Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F] PBR111
Description: Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F] PBR111
Description: Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Study: NCT01010373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS101
Description: 3 mg/m2 AS101 will be given intravenously (IV) three times per week.
Study: NCT04263337

Intervention type: DRUG
Group type: OTHER
Intervention: [18F] PBR111
Description: Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F] PBR111
Description: Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Study: NCT03663101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
Study: NCT03751696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Coaching
Description: 4 sessions of 1-1.5-hour group coaching intervention within 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS self-help tips
Description: 4 mental well-being tips through sms within 8 weeks
Study: NCT01999868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh \<= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh \> 100 kg at study entry will receive 90 mg of ustekinumab.
Study: NCT03663101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
Study: NCT01999868

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh \<= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh \> 100 kg at study entry will receive 90 mg of ustekinumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.~Dose:~125 mg sub-cutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UST Placebo
Description: The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABA Placebo
Description: The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
Study: NCT03276039

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma pentraxin-3
Description: Plasma pentraxin-3 was measured using ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma pentraxin-3
Description: Plasma pentraxin-3 was measured using ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma pentraxin-3
Description: Plasma pentraxin-3 was measured using ELISA
Study: NCT00644228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT00644228

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO
Study: NCT04263337

Intervention type: DRUG
Group type: OTHER
Intervention: [18F] PBR111
Description: Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F] Flortaucipir
Description: Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F] Flortaucipir
Description: Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Study: NCT00644228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT00662636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study (cohort II only)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study (cohort II only)
Study: NCT04282980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2618
Description: Oral kinase inhibitor